CORRIE WILLIS: Open Payments
NPI 1891771010 · KIRKSVILLE, MO. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$626 in 40 payments from 10 companies in 2025. Trend: 2023 $199 · 2024 $352 · 2025 $626
Food & beverage: $626
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 17 | $184 |
| Neurocrine BioSciences, Inc. | 6 | $139 |
| Janssen Pharmaceuticals, Inc | 3 | $55 |
| E.R. Squibb & Sons, L.L.C. | 3 | $49 |
| Teva Pharmaceuticals USA, Inc. | 2 | $37 |
| Otsuka America Pharmaceutical, Inc. | 2 | $37 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 2 | $36 |
| Lundbeck LLC | 2 | $35 |
| Axsome Therapeutics, Inc. | 2 | $34 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $20 |
Products named: VRAYLAR, INGREZZA, INVEGA SUSTENNA, REXULTI, COBENFY, AUSTEDO XR, CAPLYTA, Auvelity.
Industry payments across MO — which companies pay providers there.
